B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...
BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...
MedPage Today on MSN
Another B-Cell Drug for Lupus Hits the Mark
Phase III results put obinutuzumab in line for approval ...
Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, immunotherapy is referred to treating cancer. As tumors progress, they secrete ...
Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors As of September 2, 2024, 129 patients with LBCL (HGBCL ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results